15 Paid Clinical Research Studies in Santa Monica, California

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with

📍 Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California

💵 Patients will receive Voyager V1 as a direct to tumor injection (IT) in all 3 cancer groups and cemiplimab via IV infusi

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

This is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma.

📍 Providence Saint John's Cancer Institute — Santa Monica, California

💵 Participants may receive study treatment up to 2 years or until tumor progression, unacceptable toxicity, death, or pati

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic

📍 Research Site — Santa Monica, California

💵 In the dose expansion portion of the study in front-line (1L) pancreatic patients, participants will receive AB680 at th

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known S

📍 UCLA Hematology/Oncology — Santa Monica, California

💵 The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerabil

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-bas

📍 University of California Los Angeles UCLA - Cancer Care - Santa Monica — Santa Monica, California

💵 Subjects will receive futibatinib in combination with pembrolizumab plus standard of care (SOC) chemotherapy during indu

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in combination with Opdivo (nivilumab) for the treatment patients with of metastatic, advanced, or

📍 Sarcoma Oncology Research Center — Santa Monica, California

💵 All participants will receive open-label AL3818 with nivolumab.

A Clinical Trial to Examine the Efficacy of a Supplement to Support Healthy Hair and Skin

This is a triple-blinded, randomized, placebo-controlled clinical trial designed to evaluate the efficacy of Scale Media's Live Conscious Beyond Collagen supplement on overall hair

📍 Citruslabs — Santa Monica, California

SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer treatment, in two study cohorts: * Clinically advanced Ewing's Sarcoma patients who have

📍 Sarcoma Oncology Research Center — Santa Monica, California

💵 Study patients will receive oral SM-88, with scheduled safety and efficacy evaluations.

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced soli

📍 Sarcoma Oncology Research Center / Cancer Center of Southern California — Santa Monica, California

💵 Patients will receive gemcitabine 600 mg/m2 (Max: 1000 mg) i.v.

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

This is an open label, dose-seeking phase 1/2 study using escalating doses of TRABECTEDIN given intravenously with defined doses of IPILIMUMAB and NIVOLUMAB based on preliminary re

📍 Sarcoma Oncology Research Center — Santa Monica, California

💵 Expansion Phase 2 of Study: Following dose escalation, an additional 22-28 previously untreated patients will receive TR

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

📍 Sant P Chawla — Santa Monica, California

💵 A total of 80 patients will receive trabectedin 0.5 mg/m2 as 24 hour continuous intravenous infusion (CIV) on D1 and D8,

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen

📍 Sarcoma Oncology Center — Santa Monica, California

💵 If this dose is tolerated, the next patient will receive an increased dose of BC1.

The Effects of a Nutritional Supplement on Sleep Quality

This study is a randomized, double-blind, placebo-controlled study of N=140 adult men and women with sub-clinical sleep issues. This study to assess the effect of a novel dietary s

📍 Citruslabs — Santa Monica, California

Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, r

📍 UCLA — Santa Monica, California

💵 Following determination of an RP2D, an additional 6 subjects will receive TRE-515 at the RP2D to gain additional experie

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fig

📍 UCLA Health-Santa Monica Cancer Care (Cancer Care - Santa Monica) — Santa Monica, California

💵 Participants may receive TAK-188 for up to 1 year.